Reid Huber
InvestorPartner at Third Rock Ventures
East Coast
Writes $100K – $5M checks · typically $1.5M
About
Reid Huber is a Partner at Third Rock Ventures, which he joined in 2018, where he works on the formation, development and strategy of the firm's portfolio companies. He brings more than 25 years of operating experience in biotechnology, including as a member of the founding scientific team at Incyte in 2002, where he later served as Executive Vice President and Chief Scientific Officer. Earlier in his career he held roles of increasing responsibility at Dupont Pharmaceuticals and Bristol-Myers Squibb, and he completed postdoctoral training at the National Institutes of Health. His investing interests center on companies combining disease genetics, data science and translational medicine to create new medicines.
Beyond investing
- Founded
- Was a member of the founding scientific team at Incyte in 2002.
- Education
- Earned a B.S. in Molecular Genetics and Biochemistry from Murray State University. Holds a Ph.D. in Human Molecular Genetics from Washington University School of Medicine in St. Louis.
From Reid's own website — common ground for a warm intro.
Experience
- Third Rock VenturesPartnercurrent2018 — presentBoston, MA
- Rapport TherapeuticsDirectorcurrent2022 — presentBoston, Massachusetts, United States
- Rapport TherapeuticsCEO2022 — 2023Boston, Massachusetts, United States
- Merida BiosciencesChairpersoncurrent2024 — presentCambridge, MA
- Merida BiosciencesCEO2024 — 2025Cambridge, Massachusetts, United States
- Synnovation TherapeuticsDirectorcurrent2023 — presentWilmington, Delaware, United States
- Syremis TherapeuticsDirectorcurrent2025 — presentBoston, Massachusetts, United States
- Terremoto BiosciencesDirectorcurrent2021 — presentSan Francisco Bay Area
- Asher BiotherapeuticsDirectorcurrent2021 — present
- insitroBoard Observercurrent2019 — presentSan Francisco Bay Area
- MOMA TherapeuticsDirectorcurrent2020 — present
- MOMA TherapeuticsCEO2020 — 2021Cambridge
- Eastern New Enlgand Board of the American Cancer SocietyDirectorcurrent2020 — presentBoston, Massachusetts, United States
- Partners HealthCare, Innovation Growth BoardDirectorcurrent2019 — presentCambridge, MA
- Bellicum Pharmaceuticals, Inc.Director2014 — 2024Houston, TX
- Tango TherapeuticsDirector2019 — 2023Cambridge, MA
- The Andrew McDonough B+ FoundationDirector2017 — 2019Wilmington, Delaware
- IncyteExecutive Vice President, Chief Scientific Officer2011 — 2018Wilmington, Delaware
- IncyteExecutive Director, Clinical Development2007 — 2011
- IncyteDirector, Applied Technology2005 — 2007
Education
- Washington University School of Medicine in St. LouisPhD, Molecular Genetics/Biochemistry1994 — 1998
- Murray State UniversityBS, Molecular Genetics/Biochemistry1991 — 1994
Skills & more
+6 more
PharmacologyMolecular BiologyBiochemistryBiomarker DiscoveryFDAPharmaceutical IndustryFrom Reid's professional profile.
Same school
Also attended Washington University School of Medicine in St. Louis12
+ 6 more
